Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Emmanuelle Le Chatelier et al.|Science|2017Cited by 5.4k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung CancerLecia V. Sequist, D. Ross Camidge, Jean‐Charles Soria et al.|New England Journal of Medicine|2015Cited by 664
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Benjamin Besse, Bertrand Routy et al.|Nature Medicine|2022Cited by 637
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoîne Italiano, Vincent Ribrag, Jean‐Charles Soria et al.|The Lancet Oncology|2018Cited by 614
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Laurence Zitvogel, Takahiro Yamazaki et al.|Cell Research|2019Cited by 246